| Patient Safety |
1 |
1 |
| Dermatitis |
0 |
0.95 |
| Otolaryngology |
0 |
0.87 |
| Child |
0 |
0.45 |
| Off-Label Use |
0 |
0.45 |
| Atopic Dermatitis |
0 |
0.43 |
| Concerns of Elderly |
0 |
0.32 |
| Geriatrics |
0 |
0.32 |
| Adverse Effects |
0 |
0.26 |
| Pruritus |
0 |
0.26 |
| Revenue and Practice Management |
0 |
0.26 |
| Asthma |
0 |
0.22 |
| Bullous Pemphigoid |
0 |
0.19 |
| Insurance |
0 |
0.19 |
| Primary Care |
0 |
0.19 |
| Prurigo Nodularis |
0 |
0.19 |
| Eosinophilic Esophagitis |
0 |
0.18 |
| Health Insurance |
0 |
0.18 |
| Allergic Rhinitis |
0 |
0.17 |
| Biologic Therapy |
0 |
0.17 |
| Urticaria and Angioedema |
0 |
0.17 |
| Cornea and External Disease |
0 |
0.16 |
| Chronic Urticaria |
0 |
0.14 |
| Alopecia Areata |
0 |
0.13 |
| California |
0 |
0.13 |
| Conjunctivitis |
0 |
0.13 |
| Drug Reaction |
0 |
0.13 |
| Eosinophilia |
0 |
0.13 |
| Esophagitis |
0 |
0.13 |
| Face |
0 |
0.13 |
| Receptors |
0 |
0.13 |
| Urticaria |
0 |
0.13 |
| Alopecia |
0 |
0.12 |
| Academia |
0 |
0.11 |
| Abdomen |
0 |
0.06 |
| Allergy |
0 |
0.06 |
| Antibacterial Agents |
0 |
0.06 |
| Antifungal |
0 |
0.06 |
| Antihistamine |
0 |
0.06 |
| Antiviral Agents |
0 |
0.06 |
| Bacteria |
0 |
0.06 |
| Cervical Region |
0 |
0.06 |
| Clinical Research |
0 |
0.06 |
| Contact Dermatitis |
0 |
0.06 |
| Drug Costs |
0 |
0.06 |
| Eczema |
0 |
0.06 |
| Femoral |
0 |
0.06 |
| Fungal Infection |
0 |
0.06 |
| Gluteal Region |
0 |
0.06 |
| Graft |
0 |
0.06 |
| Healthcare and Medical Technology |
0 |
0.06 |
| Hospital |
0 |
0.06 |
| Immunocompromise |
0 |
0.06 |
| Interleukin |
0 |
0.06 |
| Keloids |
0 |
0.06 |
| Lichen Planus |
0 |
0.06 |
| Medical Literature |
0 |
0.06 |
| Rhinitis |
0 |
0.06 |
| Rhinosinusitis |
0 |
0.06 |
| Scleroderma |
0 |
0.06 |